Exciting Findings in Dry AMD Study!
Posted by: Florida Eye Microsurgical Institute in Worth Sharing...
APELLIS’ GEOGRAPHIC ATROPHY TREATMENT SLOWS RATE OF PROGRESSION OF DRY AMD A Phase 2 study of Apellis Pharmaceuticals’ APL-2 for geographic atrophy (GA) in age related macular degeneration (FILLY STUDY) has been statistically proven to reduce the rate of progression of GA by 29% when administered monthly. The drug APL-2 effects appear to increase in… Read More